Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]
, 2010 Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui +4 more
core +1 more source
Buflomedil for intermittent claudication [PDF]
, 2013 Background : Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease.
De Backer, Tine, Vander Stichele, Robert
core +2 more sources
Jurnal Penyakit Dalam Indonesia, 2017 Introduction. There are few studies regarding peripheral artery disease (PAD by intermittent claudication) on adults in Indonesia, including its risk factors.This study aims to determine relationship and comparison of PAD accompanied by intermittent ...
Naldo Sofian +2 more
doaj +1 more source
Living a burdensome and demanding life: a qualitative systematic review of the patients experiences of peripheral arterial disease [PDF]
, 2018 BackgroundPeripheral arterial disease (PAD) has a significant negative impact on the quality of life of individuals. Understanding the experiences of people living with PAD will be useful in developing comprehensive patient-centred secondary prevention ...
Abaraogu, Ukachukwu Okoroafor +3 more
core +2 more sources
Quality of life in patients with intermittent claudication [PDF]
, 2017 © 2017, The Author(s). Background: Intermittent claudication (IC) is a common condition that causes pain in the lower limbs when walking and has been shown to severely impact the quality of life (QoL) of patients.
Broadbent, E. +4 more
core +1 more source
BMC Cardiovascular Disorders, 2009 Background Disease severity and functional impairment in patients with intermittent claudication is usually quantified by the measurement of pain-free walking distance (intermittent claudication distance, ICD) and maximal walking distance (absolute ...
Prins Martin H +5 more
doaj +1 more source
Transcutaneous calf-muscle electro-stimulation : a prospective treatment for diabetic claudicants? [PDF]
, 2016 Background: First-line therapy for claudicants with diabetes include supervised exercise programmes to improve walking distance. However, exercise comes with a number of barriers and may be contraindicated in certain conditions. The aim of this study was
Ellul, Christian, Gatt, Alfred
core +1 more source
Patient Characteristics and Comorbidities Influence Walking Distances in Symptomatic Peripheral Arterial Disease: A Large One-Year Physiotherapy Cohort Study. [PDF]
PLoS ONE, 2016 OBJECTIVES:The aim of this study is to investigate the association between age, gender, body-mass index, smoking behavior, orthopedic comorbidity, neurologic comorbidity, cardiac comorbidity, vascular comorbidity, pulmonic comorbidity, internal ...
Sarah Dörenkamp +4 more
doaj +1 more source
Intermittent Claudication [PDF]
Circulation, 1955 The diagnosis and therapy of intermittent claudication are critically reviewed. A detailed, concrete and positive program is described whereby every physician can effectively treat patients with intermittent claudication without recourse to intricate diagnostic or therapeutic techniques. The value of this program is illustrated with four case reports.
openaire +2 more sources
Extracorporeal shockwave therapy for the treatment of lower limb intermittent claudication: Study protocol for a randomised controlled trial (the SHOCKWAVE 1 trial) [PDF]
, 2017 © 2017 The Author(s). Background: Peripheral arterial disease (PAD) has a population prevalence of 4.6% with intermittent claudication (IC) presenting as one of the earliest and most common symptoms.
Carradice, Daniel +8 more
core +1 more source